Mayne Pharma adds a generic PROTOPIC ® to US portfolio

ASX Announcement MAYNE PHARMA ADDS GENERIC PROTOPIC® TO US DERMATOLOGY PORTFOLIO 12 January 2022, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of tacrolimus ointment, 0.1% in the United States. Tacrolimus ointment is a generic version of PROTOPIC®, indicated for the treatment of atopic dermatitis. According to IQVIA, the annual US market sales for tacrolimus ointment were US$80 million for the twelve months ending November 20211. Mayne Pharma entered into a license and supply agreement with Sandoz AG to distribute tacrolimus ointment in non-retail channels. Mayne Pharma’s CEO Scott Richards said, “We are pleased to partner with Sandoz, a global leader in generic pharmaceuticals and biosimilars. Mayne Pharma has launched nine dermatology products in FY22 targeting markets with IQVIA sales of more than US$380 million1.” “Mayne Pharma’s US portfolio of brand and generic products covers 9 of the top 15 most prescribed molecules by dermatologists and treat a range of dermatological conditions. We continue to have active discussions with other parties around further product collaborations that will continue to add breadth to our portfolio to satisfy the needs of dermatologists and patients.” For further information contact: Lisa Pendlebury (VP Investor Relations & Communications) +61 419 548 434, [email protected] Authorised for release to the ASX by the Chair. About Mayne Pharma Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. 1 IQVIA, MAT Sales, November 2021 ASX Announcement Page 2 Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds. PROTOPIC® is a registered trademark of a third party.

The release as fetched from its publisher. maynepharma.com ↗